Emcure Pharmaceuticals Limited has announced the completion of its acquisition of the remaining 20.42% stake in Zuventus Healthcare Limited, making it a wholly-owned subsidiary. This strategic move strengthens Emcure's position in the pharmaceutical sector and consolidates its control over Zuventus' operations.

Acquisition Details

The acquisition involved the purchase of 4,095,180 equity shares of Zuventus Healthcare, representing the 20.42% stake that was not previously owned by Emcure. The transaction was completed for an aggregate consideration of Rs. 7,249.00 million, paid in cash.

Timeline and Approval

The acquisition process began on June 21, 2025, when Emcure's Board of Directors approved the purchase of the remaining shares from individual shareholders. The company successfully concluded the acquisition by October 3, 2025, ahead of the initially projected completion date of September 30, 2025.

Impact on Ownership Structure

Prior to this transaction, Emcure Pharmaceuticals held a 79.58% stake in Zuventus Healthcare. With the acquisition of the remaining shares, Emcure now owns 100% of Zuventus, transforming it into a wholly-owned subsidiary.

About Zuventus Healthcare

Zuventus Healthcare Limited, incorporated on May 27, 2002, is involved in the business of dealing with various types of pharmaceutical medicaments in healthcare. The company has shown steady growth over the past few years, as evidenced by its financial performance:

For the financial year ended March 31, 2025, Zuventus reported a turnover of Rs. 10,798.99 million and a profit after tax (PAT) of Rs. 1,347.82 million.

Strategic Implications

This acquisition aligns with Emcure Pharmaceuticals' strategy to strengthen its presence in the pharmaceutical industry. By gaining full ownership of Zuventus Healthcare, Emcure is poised to streamline operations, enhance synergies, and potentially accelerate growth in the healthcare sector.

The move is expected to provide Emcure with greater control over Zuventus' operations and allow for more integrated decision-making processes. It may also lead to improved operational efficiencies and potentially expanded market reach for both entities.

As the pharmaceutical landscape continues to evolve, this strategic acquisition positions Emcure Pharmaceuticals to capitalize on Zuventus' established presence and expertise in the healthcare market, potentially driving innovation and growth in the coming years.

Emcure Pharmaceuticals , a leading Indian pharmaceutical company, has announced strong financial results for the first quarter of fiscal year 2025, demonstrating significant growth across various markets and operational segments.

Financial Highlights

The company reported impressive numbers for Q1FY25:

Emcure's EBITDA margins stood at a healthy 19.8%, reflecting the company's operational efficiency.

Market Performance

Emcure's growth was well-balanced across domestic and international markets:

• Domestic Business: Contributed Rs 909.00 crore, marking a 14% growth
• International Operations: Generated Rs 906.00 crore, showing a robust 19.5% increase

The company's international performance was particularly noteworthy:

• North America: Exhibited exceptional growth of 72.3%
• Europe: Demonstrated steady growth of 8.6%

Strategic Developments

Emcure's domestic growth received a boost from its distribution partnership with Sanofi for cardiovascular brands. The company reported that these brands are now fully integrated into its operations, contributing to its strong performance in the Indian market.

Market Position

The quarterly results reaffirm Emcure Pharmaceuticals' strong position in the pharmaceutical industry:

• Maintains its rank as the 12th largest pharmaceutical company in India
• Operates in over 70 countries globally, showcasing its extensive international presence

The company's balanced growth across domestic and international markets, coupled with strategic partnerships and a diverse geographical presence, positions Emcure Pharmaceuticals well for continued success in the competitive pharmaceutical landscape.